PTRF-IL33-ZBP1 signaling mediating macrophage necroptosis contributes to HDM-induced airway inflammation

Juan Du1,2, Yahui Liu1,2, Gelei Lan1,2

  • 1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cell Death & Disease
|July 15, 2023
PubMed

Insights

Polymerase 1 and transcript release factor (PTRF) deficiency reduces house dust mite-induced airway inflammation by inhibiting Z-DNA binding protein 1 (ZBP1)-mediated necroptosis in macrophages. This pathway, involving IL-33, offers a potential therapeutic target for asthma.

Area of Science:

  • Immunology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • Asthma is linked to interleukin 33 (IL-33) and Z-DNA binding protein 1 (ZBP1)-induced necroptosis.
  • House dust mite (HDM) is a major asthma allergen.
  • The role of Polymerase 1 and transcript release factor (PTRF/Cavin-1) in HDM-induced inflammation is unknown.

Purpose of the Study:

  • To investigate if PTRF mediates HDM-induced macrophage necroptosis and airway inflammation via IL-33 and ZBP1.
  • To explore the PTRF-IL33-ZBP1 signaling pathway in asthma pathogenesis.

Main Methods:

  • Utilized an HDM-induced asthma mouse model with PTRF deficiency.
  • Analyzed lung tissue and macrophage cultures for IL-33, ZBP1, p-RIPK3, and p-MLKL expression.
  • Investigated the effects of IL-33 and HDM co-treatment on macrophage necroptosis markers.

Main Results:

  • PTRF deficiency reduced lung IL-33, ZBP1, and necroptosis markers (p-RIPK3, p-MLKL) in HDM-induced asthma.
  • HDM treatment increased ZBP1 and necroptosis markers in macrophages, reversed by Cavin-1 deletion.
  • IL-33 deficiency decreased ZBP1 and necroptosis markers; IL-33 plus HDM synergistically increased these markers.

Conclusions:

  • PTRF mediates HDM-induced macrophage ZBP1/necroptosis and airway inflammation, partly via bronchial epithelial cell-derived IL-33.
  • The PTRF-IL33-ZBP1 signaling pathway is crucial in HDM-induced asthma.
  • Targeting this pathway may offer a novel therapeutic strategy for airway inflammation.